1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,700 | 6,000 | 11:27 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01:42 | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals appoints EVPs | 1 | Stockwatch | ||
| Mo | Eupraxia names new executives, relocates operations | 1 | Investing.com | ||
| EUPRAXIA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mo | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Strengthens Executive Leadership Team to Support Next Phase of Growth | 45 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, July 13, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| Mi | Eupraxia Pharmaceuticals Inc: Eupraxia Pharmaceuticals appoints three directors | 1 | Stockwatch | ||
| 07.07. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 07.07. | Eupraxia Pharmaceuticals verstärkt Verwaltungsrat mit drei Neuzugängen | 2 | Investing.com Deutsch | ||
| 07.07. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization | 260 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 25.06. | Oppenheimer initiates Eupraxia stock with Outperform rating | 1 | Investing.com | ||
| 25.06. | Oppenheimer startet Coverage für Eupraxia mit "Outperform"-Rating und hohem Kursziel | 1 | Investing.com Deutsch | ||
| 22.06. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 19.06. | Eupraxia Pharmaceuticals Inc: Eupraxia shareholders approve all matters at AGM | 1 | Stockwatch | ||
| 19.06. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders | 319 | GlobeNewswire (Europe) | VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging... ► Artikel lesen | |
| 28.05. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 20.05. | Stifel initiates Eupraxia Pharmaceuticals stock with buy rating | 2 | Investing.com | ||
| 12.05. | Eupraxia Pharmaceuticals Inc.: Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results | 192 | GlobeNewswire (Europe) | Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI Completion of a $63.2 million public offering to enable clinical trials of EP-104GI in additional indications... ► Artikel lesen | |
| 12.05. | EUPRAXIA PHARMACEUTICALS INC. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 06.05. | Stocks in Play: Eupraxia Pharmaceuticals Inc. | 1 | Baystreet.ca | ||
| 06.05. | Eupraxia präsentiert positive Studiendaten zur Behandlung von Eosinophiler Ösophagitis | 3 | Investing.com Deutsch | ||
| 06.05. | Eupraxia reports EoE trial data on inflammation and fibrosis | 1 | Investing.com | ||
| 05.05. | Eupraxia reports endoscopy score data from EoE trial | 1 | Investing.com |
1 2 3 4 Weiter >>
70 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 6,330 | +0,19 % | CLINUVEL PHARMACEUTICALS LIMITED: SCENESSE approved for EPP in Canada | ||
| EDITAS MEDICINE | 2,640 | -4,69 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,906 | -1,20 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| CELLECTAR BIOSCIENCES | 2,650 | +0,76 % | Cellectar Biosciences, Inc. - 8-K, Current Report | ||
| CYTODYN | 0,192 | 0,00 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,170 | -1,76 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 6,960 | -1,14 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 22,320 | -4,08 % | JPMorgan resumes Denali Therapeutics stock coverage with Overweight rating | ||
| CEL-SCI | 1,100 | -1,79 % | CEL-SCI launches confirmatory study for head and neck cancer drug | ||
| CYTOKINETICS | 71,20 | -1,41 % | Will Myqorzo Drive Cytokinetics Higher Despite Competitive Pressure? | ||
| COHERUS ONCOLOGY | 1,399 | +7,95 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CURIS | 4,510 | +9,17 % | XFRA CUS1: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,206 | -1,23 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,754 | +3,92 % | Fate Therapeutics, Inc.: Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate | First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited... ► Artikel lesen | |
| FAETH THERAPEUTICS | 33,430 | +0,21 % | Sensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer | - Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement -
- Company changed name to Faeth... ► Artikel lesen |
EUPRAXIA PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,200 (+3,64 %) liegt der Kurs bei 5,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EUPRAXIA PHARMACEUTICALS INC finden Sie auf Wallstreet Online.